/

SCNX

Scienture Holdings, Inc.Open

3.28+0.04 +1.23%USD

NasdaqCM · as of Oct 14, 14:33 ET · 15m delay

Open

3.33

Prev close

3.24

Day range

3.273.52

52-week range

3.2365.00

Volume

36.01K0.19×

Mkt cap

5.39M

P/E ttm

—

Fwd P/E

—

EPS ttm

-52.75

Div yield

0.00%

Earnings

—

From 52w high

−94.95%

Price Chart

Yahoo Finance · delayed

SCNXOct 14, 2026O 3.33H 3.52L 3.27C 3.28+0.04 (+1.23%)Vol 36.01K

SMA 508.18
SMA 2009.79

1Y change −81.78% since Oct 13, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

SCNX Scienture Holdings, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −20.58%
1 month: −61.30%
3 months: −67.84%
6 months: −66.62%
Year to date: −74.27%
1 year: −82.00%

Valuation & ownership

Market cap: 5.39M
Enterprise value: 7.82M
P/E (ttm): —
Forward P/E: —
PEG ratio: —
Price / book: 0.08
Price / sales (ttm): 6.56
EV / EBITDA: -0.63
EPS (ttm): -52.75
EPS (forward): 0.000000
Beta (5y monthly): 4.08
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 1.64M
Float: 1.28M
Short % of float: 3.41%
Short ratio (days): 0.89
Held by insiders: 22.08%
Held by institutions: 5.30%
Avg volume (3m): 188.65K
50-day average: 8.30
200-day average: 9.84
52-week change: −82.00%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): oversold 17.4
vs 50-day SMA: −59.91%
vs 200-day SMA: −66.49%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 20.23%
Realised vol (20d, ann.): 156.3%
From 52-week high: −94.95%
From 52-week low: +1.55%

ANR

Analyst Consensus

1 analysts

Consensus

Buy

2.00 on a 1 (strong buy) – 5 (sell) scale

Mean target

37.50

+1,043.29% implied

Low 37.50Median 37.50High 37.50

Recommendation trend

Now1 / 0 / 0
1m ago1 / 0 / 0
2m ago

DES

About Scienture Holdings, Inc.

Yahoo Finance profile

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.

Sector: Healthcare
Industry: Pharmaceutical Retailers
Employees: 4
Headquarters: Commack, NY, United States
Website: scienture.com
Officers: Dr. Shankar Hariharan Ph.D. Founder, Co-CEO & Executive Chairman
Dr. Narasimhan Mani M.B.A., Ph.D. President, Co-CEO, Interim CFO & Director
Mr. Rahul Surana M.B.A., Ph.D. Executive VP & COO of Scienture LLC
Ms. Michele Rath

SEAS

Seasonality · SCNX

2014–2026 · monthly returns

Strongest month Jun +24.45%Weakest month Oct −11.72%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-11.0	-5.3	-33.7	37.2	5.6	-15.3	8.9	2.1	-33.2	-49.5			−74.3%
2025	-36.0	-31.5	-45.7	-35.4	-6.0	19.0	86.5	-49.7	-12.8	-8.7	-22.8	-14.9	−91.6%
2024	-19.7	128.3	7.6	-41.8	10.2	70.0	-13.3	-18.4	-4.1	-3.0	0.0	-17.7	+16.4%
2023	4.2	-0.7	-29.3	13.2	-16.2	210.7	-43.1	3.0	-8.0	-17.2	0.5	-11.2	−14.0%
2022	-14.0	-13.3	57.4	-38.6	-8.9	4.7	2.5	-30.1	-2.6	-21.2	-36.5	-28.7	−82.9%
2021	4.5	13.0	-16.2	-17.0	-16.8	22.1	12.4	8.2	-8.5	-13.1	-22.7	-28.7	−55.4%
2020	13.6	-29.3	8.5	35.7	-31.3	11.9	12.7	-13.8	7.2	-33.1	41.1	-10.3	−19.8%
2019	76.0	-5.3	-6.0	-6.4	2.3	22.2	27.3	28.6	46.7	-18.9	16.8	-12.0	+266.7%
2018	-15.6	-42.1	127.3	-2.0	8.2	-5.7	0.0	-14.0	16.3	-20.0	-20.0	-6.3	−33.3%
2017	-13.0	112.5	-11.8	-13.3	15.4	-26.7	-5.8	0.0	-20.8	-46.3	0.5	103.6	−2.2%
2016	-9.1	-20.0	27.5	-7.8	-14.9	17.3	-35.0	19.7	-23.3	16.1	7.7	-34.3	−58.2%
2015	0.0	-2.9	3.0	-11.8	16.7	-11.4	-3.2	-16.7	-20.0	0.0	-8.0	19.6	−35.3%
2014			0.0	0.0	96.7	-40.7	-2.9	-20.6	3.7	25.0	0.0	-2.9	+13.3%

INSD

Insider Activity · SCNX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

7.81M shares

Sells, 6 months

27.4K shares

Net shares

+7.79M

Net change in insider shares

−104.90%

Date	Insider	Transaction	Shares	Value
Feb 19, 2026	Narasimhan ManiChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	1.55M	—
Feb 19, 2026	Hariharan Shankar Ph.D.Chief Executive Officer	Stock Award(Grant) at price 0.00 per share.	1.55M	—
May 14, 2025	Sherb Eric MichaelChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	50K	—
Sep 18, 2024	Narasimhan ManiChief Executive Officer	—	1.36M	—
Sep 18, 2024	Hariharan Shankar Ph.D.Chief Executive Officer	—	2.27M	—

SCNX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

SCNX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Scienture Holdings, Inc.

Seasonality · SCNX

Insider Activity · SCNX

Congress Trades · SCNX

Investors Holding SCNX

Investors Holding SCNX

Congress Trades · SCNX

Insider Activity · SCNX

Seasonality · SCNX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Scienture Holdings, Inc.

Financial Snapshot

Earnings & Dividends

News